TY - JOUR
T1 - Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases
T2 - A multi-institutional study
AU - Nakagawa, Yasunori
AU - Suzuki, Kenshi
AU - Hirose, Takayuki
AU - Chou, Takaaki
AU - Fujisawa, Shin
AU - Kida, Michiko
AU - Usuki, Kensuke
AU - Ishida, Yoji
AU - Taniguchi, Shuichi
AU - Kouzai, Yasuji
AU - Tomoyasu, Shigeru
AU - Miyazaki, Koji
AU - Higashihara, Masaaki
AU - Ando, Kiyoshi
AU - Aoki, Sadao
AU - Arai, Ayako
AU - Akiyama, Nobu
AU - Hatake, Kiyohiko
AU - Okamoto, Shinichiro
AU - Dan, Kazuo
AU - Ohyashiki, Kazuma
AU - Urabe, Akio
PY - 2011/2
Y1 - 2011/2
N2 - A multi-institutional study was conducted to assess efficacy and safety of biapenem (BIPM), a carbapenem antibiotic, as an initial-stage therapeutic agent for febrile neutropenia (FN) in patients with hematopoietic diseases. A total of 216 patients from 25 medical institutions were enrolled in this study; of these, 204 were included in the safety analysis and 178 in the efficacy analysis. The combined (excellent and good) response rate was 67.9%, and antipyretic effect (subsidence + tendency to subsidence) was achieved within 3 and 5 days of treatment in 67.3 and 75.9% of patients, respectively. Thus, the clinical responses were gratifying. A response rate of 61.7% (37/60) was observed even in high-risk FN patients in whom neutrophil counts prior to and at 72 h after the start of BIPM were ≤100/μl. BIPM is considered to be a highly promising drug, with prompt onset of clinical benefit, as an initial-stage therapeutic agent for the treatment of FN in patients with hematopoietic diseases.
AB - A multi-institutional study was conducted to assess efficacy and safety of biapenem (BIPM), a carbapenem antibiotic, as an initial-stage therapeutic agent for febrile neutropenia (FN) in patients with hematopoietic diseases. A total of 216 patients from 25 medical institutions were enrolled in this study; of these, 204 were included in the safety analysis and 178 in the efficacy analysis. The combined (excellent and good) response rate was 67.9%, and antipyretic effect (subsidence + tendency to subsidence) was achieved within 3 and 5 days of treatment in 67.3 and 75.9% of patients, respectively. Thus, the clinical responses were gratifying. A response rate of 61.7% (37/60) was observed even in high-risk FN patients in whom neutrophil counts prior to and at 72 h after the start of BIPM were ≤100/μl. BIPM is considered to be a highly promising drug, with prompt onset of clinical benefit, as an initial-stage therapeutic agent for the treatment of FN in patients with hematopoietic diseases.
KW - Biapenem
KW - Febrile neutropenia
KW - Hematopoietic diseases
UR - http://www.scopus.com/inward/record.url?scp=79951554132&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79951554132&partnerID=8YFLogxK
U2 - 10.1007/s10156-010-0075-3
DO - 10.1007/s10156-010-0075-3
M3 - Article
C2 - 20602137
AN - SCOPUS:79951554132
SN - 1341-321X
VL - 17
SP - 58
EP - 67
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 1
ER -
